Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized multifactorial primary prevention trial in high-risk subjects eligible for lung cancer CT screening
2024-513660-26-00Phase 2Authorised
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- Aug 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of aspirin and cytisinicline in nicotine dependence and bronchial carcinoma (3 arms), sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Primary endpoint: Reduction in elevated C-reactive protein after one year. Planned start Aug 2024; status: authorised.
02
Drugs
aspirincytisinicline
03
Conditions
nicotine dependencebronchial carcinoma
Beyond the preview
Go deeper on 2024-513660-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513660-26-00.